IntraBio Announces U.S. FDA Approval of Aqneursa (levacetylleucine) for Ataxia-Telangiectasia
RegulatoryapprovedAqneursaPositive
AI Analysis
Summary
IntraBio announced U.S. FDA approval of Aqneursa (levacetylleucine) for Ataxia-Telangiectasia, a rare neurodegenerative disease. This is a market-moving regulatory approval for a novel therapy in the rare disease space.
Outcome Details
U.S. FDA approval of Aqneursa (levacetylleucine) for Ataxia-Telangiectasia
Importance:8/10
Sentiment:
0.90
FDA approvalrare diseaseneurodegenerativesmall moleculeataxia-telangiectasia
Read the original article
Published by Drugs.com New Drug Approvals on September 18, 2026 8:09 PM